Inovalon Gains 2.1%, to Present at NASDAQ Investor Program
Inovalon closed at $18.26 and was trading below 20-, 50-, and 100-day moving averages.
The Amsurg-Envision Material Adverse Effect Clause: Part 2
In this part of the series, we’ll look at the MAE clause of the Amsurg (AMSG) merger agreement with Envision Healthcare (EVHC) and how Amsurg could back out of the deal.
What’s the Main Regulatory Risk of the Envision-Amsurg Deal?
In the risk arbitrage world, a 2.8% annualized return is pretty small. There’s some overlap that could concern regulators. The main risk would be the timing risk.
Can the Amsurg-Envision Transaction Get Antitrust Approval?
In the case of Amsurg (AMSG) and Envision (EVHC), the gating item will depend on how closely antitrust regulators look at the transaction.
What’s the Rationale for the Amsurg-Envision Merger?
Amsurg and Envision are merging. Envision shareholders will receive 0.334 shares of Amsurg stock for each share of Envision they hold.
Amsurg and Envision Merge to Form a Healthcare Services Juggernaut
On June 15, Amsurg (AMSG) and Envision (EVHC) announced a merger. Envision will hold 53% of the new company and Amsurg will hold 47%.